デフォルト表紙
市場調査レポート
商品コード
1004983

妊娠性絨毛性疾患の世界市場(2020年~2027年)

Global Gestational Trophoblastic Disease Market - 2020-2027

出版日: | 発行: DataM Intelligence | ページ情報: 英文 180 Pages | 納期: 約2営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=111.41円
妊娠性絨毛性疾患の世界市場(2020年~2027年)
出版日: 2021年05月12日
発行: DataM Intelligence
ページ情報: 英文 180 Pages
納期: 約2営業日
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

世界の妊娠性絨毛性疾患市場の主な成長要因には、高年齢出産や子宮外妊娠の増加、積極的な喫煙習慣の増加などの疾患に影響を及ぼすリスク要因の増加、腫瘍学分野における技術革新の進展、標的療法への注目の高まり、有利な政府政策などが挙げられます。ただし、高い治療費は、市場の成長を妨げる可能性があります。

当レポートは、世界の妊娠性絨毛性疾患市場について調査しており、市場の機会や影響、成長および抑制要因、タイプ・治療タイプ・エンドユーザー・地域別の市場分析、競合情勢、主要企業のプロファイルなどの情報を提供しています。

目次

第1章 世界の妊娠性絨毛性疾患市場の調査手法と範囲

  • 調査手法
  • 調査の目的と調査範囲

第2章 世界の妊娠性絨毛性疾患市場-市場の定義と概要

第3章 世界の妊娠性絨毛性疾患市場-エグゼクティブサマリー

  • タイプ別の市場内訳
  • 治療タイプ別の市場内訳
  • エンドユーザー別市場内訳
  • 地域別の市場内訳

第4章 世界の妊娠性絨毛性疾患市場-市場力学

  • 市場に影響を与える要因
    • 成長要因
    • 抑制要因
    • 市場機会
    • 影響分析

第5章 世界の妊娠性絨毛性疾患市場-業界分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析
  • 償還分析
  • アンメットニーズ

第6章 世界の妊娠性絨毛性疾患市場-COVID-19分析

  • 市場でのCovid-19の分析
    • COVID-19以前の市場シナリオ
    • 現在の市場シナリオ
    • COVID-19以後または今後のシナリオ
  • Covid-19における価格動向
  • 需要と供給のスペクトル
  • パンデミック時の市場に関連する政府のイニシアチブ
  • メーカーの戦略的イニシアチブ
  • 結論

第7章 世界の妊娠性絨毛性疾患市場-タイプ別

  • イントロダクション
  • タイプセグメント別の市場規模分析および前年比成長分析
  • がんのタイプ別の市場魅力指数
    • 絨毛がん
    • 胎盤部トロホブラスト腫瘍
    • 上皮性絨毛腫瘍
    • その他

第8章 妊娠性絨毛性疾患の世界の市場-治療タイプ別

  • イントロダクション
  • 治療タイプ別の市場規模分析および前年比成長分析
  • 治療タイプ別の市場魅力指数
    • 化学療法
    • 手術
    • 放射線治療
    • その他

第9章 世界の妊娠性絨毛性疾患市場-エンドユーザー別

  • イントロダクション
  • エンドユーザーセグメント別の市場規模分析および前年比成長分析
  • エンドユーザーセグメント別の市場魅力指数
    • 病院
    • クリニック
    • がん調査機関
    • その他

第10章 世界の妊娠性絨毛性疾患市場-地域別

  • イントロダクション
  • 地域別の市場規模分析、および前年比成長分析
  • 地域別市場魅力指数
  • 北米
    • イントロダクション
    • 主要地域ごとの力学
    • タイプ別:市場規模分析、および前年比成長分析
    • 治療タイプ別:市場規模分析、および前年比成長分析
    • エンドユーザー別:市場規模分析、および前年比成長分析
    • 国別:市場規模分析、および前年比成長分析
  • 欧州
    • イントロダクション
    • 主要地域ごとの力学
    • タイプ別:市場規模分析、および前年比成長分析
    • 治療タイプ別:市場規模分析、および前年比成長分析
    • エンドユーザー別:市場規模分析、および前年比成長分析
    • 国別:市場規模分析、および前年比成長分析
  • 南米
    • イントロダクション
    • 主要地域ごとの力学
    • タイプ別:市場規模分析、および前年比成長分析
    • 治療タイプ別:市場規模分析、および前年比成長分析
    • エンドユーザー別:市場規模分析、および前年比成長分析
    • 国別:市場規模分析、および前年比成長分析
  • アジア太平洋
    • イントロダクション
    • 主要地域ごとの力学
    • タイプ別:市場規模分析、および前年比成長分析
    • 治療タイプ別:市場規模分析、および前年比成長分析
    • エンドユーザー別:市場規模分析、および前年比成長分析
    • 国別:市場規模分析、および前年比成長分析
  • 中東とアフリカ
    • イントロダクション
    • 主要地域ごとの力学
    • タイプ別:市場規模分析、および前年比成長分析
    • 治療タイプ別:市場規模分析、および前年比成長分析
    • エンドユーザー別:市場規模分析、および前年比成長分析

第11章 世界の妊娠性絨毛性疾患市場-競合情勢

  • 競合シナリオ
  • 市場の位置付け/シェア分析
  • 合併と買収の分析

第12章 世界の妊娠性絨毛性疾患市場-企業プロファイル

  • Merck Healthcare KGaA
    • 企業概要
    • 製品ポートフォリオ・概要
    • 要点
    • 財務概要
  • Bristol-Myers Squibb Company,
  • Antares Pharma,
  • Novartis AG,
  • Teva Pharmaceutical Industries Ltd,
  • BP Pharmaceuticals Laboratories Company,
  • Accord Healthcare, Inc,
  • Eli Lilly and Company,
  • Sanofi,
  • Amgen Inc

第13章 世界の妊娠性絨毛性疾患市場-重要考察

第14章 世界の妊娠性絨毛性疾患市場-DataM

  • 付録
  • 当社・サービスについて
  • お問い合わせ
目次

Market Overview

The Global Gestational Trophoblastic Disease Market size was worth US$ XX billion in 2018 and is estimated to reach US$ XX billion by 2027, growing at a CAGR of XX % during the forecast period (2020-2027).

A Gestational Trophoblastic Disease (GTD) is a group of rare tumors that involve abnormal growth of cells inside a woman's uterus. These do not develop from the uterus cells like cervical cancer or endometrial (uterine lining) cancer does. Instead, these tumors begin in the cells that would normally develop into the placenta during pregnancy. GTDs begin in the layer of cells called the trophoblast that usually surrounds an embryo. Early in normal development, the cells of the trophoblast form tiny, finger-like projections known as villi. These villi grow into the lining of the uterus, and in time, the trophoblast layer develops into the placenta, the organ that protects and nourishes the growing foetus. Most GTDs are benign (not cancer), and they don't invade deeply into body tissues or spread to other parts of the body. But some are malignant (cancerous). Some signs and symptoms include Vaginal bleeding, Low red blood cell count (anemia), Swelling of the abdomen (belly), Ovarian cysts, Pre-eclampsia (toxic pregnancy). According to the type of gestational trophoblastic disease (GTD) and the stage and prognostic group of the disease, the standard treatment options are surgery, chemotherapy, and radiation therapy.

Market Dynamics

The global Gestational Trophoblastic Disease market growth is driven by the Uprising in risk factors affecting this spectrum of disease like increase in high maternal age, increase cases for ectopic pregnancies, rise in active smoking habits, growing innovations in the field of oncology and the increase focus towards targeted therapies, along with the favourable government policies are the major factors driving the market.

Uprising in risk factors affecting this spectrum of disease, is expected to drive the growth in the forecast period

Major risk factors affecting GTDs are high maternal age, increased ectopic pregnancies and active smoking habits. GTD occurs in women of childbearing age. The risk of complete molar pregnancy is highest in women over age 35 and younger than 20. As per the American Lung Association, cigarette smoking kills an expected 201,770 women annually in the U.S because the risk of ectopic pregnancy is 4 to 20 times higher in women who smoke. These factors are driving the growth of the market in the forecast period.

High treatment costs are likely to hinder the market growth.

According to the National Library of Medicine, First-line chemotherapy for low-risk gestational trophoblastic neoplasia is $9,089 average cost per cure and for high-risk it costs even high. These are one of the major factors restricting the market growth.

COVID-19 Impact Analysis

The COVID-19 pandemic has negatively impacted healthcare systems globally and also on the market growth. According to the Centers for Disease Control and Prevention (CDC) and many medical professional organizations recommended that cancer screening and other health prevention services, along with elective surgeries, be postponed unless the risks outweighed the benefits and secure the hospital infrastructure for the treatment of COVID-19 patients. Thus, the COVID-19 pandemic has impacted the On-going clinical trials too. However, the situation is expected to improve gradually

Segment Analysis

Based on the Type, the global Gestational Trophoblastic Disease market is segmented into Hydatidiform mole (complete or partial, Invasive mole), Choriocarcinoma, Placental-site trophoblastic tumor, Epithelioid trophoblastic tumor.

Gestational trophoblastic disease (GTD) is a rare form of tumor occurs in about 1 pregnancy out of 1,000 in the United States. Most of these are hydatidiform moles. Choriocarcinoma, a malignant form of gestational trophoblastic disease (GTD), is even less common, affecting around 2 to 7 of every 100,000 pregnancies.

Hydatidiform mole segment, is expected to hold the largest in the market.

The most common form of the gestational trophoblastic disease (GTD) is a hydatidiform mole, and it is also known as a molar pregnancy. It is made up of villi that have become swollen with fluid. The swollen villi grow in clusters that look like bunches of grapes. It is called a molar pregnancy, but a normal baby can't form. Still, in rare cases (less than 1 in 100), a normal foetus can develop alongside the molar pregnancy. Hydatidiform moles are not cancerous, but they can develop into cancerous GTDs. For instance, Study of the Genetic and Epigenetic Causes of Recurrent Hydatidiform Moles by Baylor College of Medicine is expected to complete by 2025 which will increase the demand for this segment.

Based on the Treatment Type, the global Gestational Trophoblastic Disease market is segmented into Chemotherapy, Surgery, Radiation therapy and Others.

Chemotherapy segment, is expected to hold the largest in the market.

Chemotherapy treatment uses anti-cancer drugs that are injected into a vein or given by mouth. These drugs enter the bloodstream and reach all areas of the body, making this treatment useful for cancers that have spread to distant organs (metastasized). Gestational trophoblastic disease (GTD) is one of the few cancers that can almost always be cured by chemo, no matter how advanced it is. The drugs that can be used to treat GTD include Methotrexate (with or without leucovorin), Actinomycin-D (dactinomycin), Cyclophosphamide (Cytoxan®), Chlorambucil, Vincristine (Oncovin®), Etoposide (VP-16), Cisplatin, Ifosfamide (Ifex®), Bleomycin, Fluorouracil (5-FU), Paclitaxel (Taxol®).

Based on End-User, the global Gestational Trophoblastic Disease market is segmented into Hospitals, Diagnostic Centers, Clinics, others.

Due to the growing patient population, the hospitals segment held the largest market share. This is mainly owing to increasing number of patients suffering from conditions which are treated in hospitals equipped with advanced infrastructure and adequate facilities. Moreover, growing number of hospitals along with adequate reimbursement policies is also contributing to the growth of this segment. Also the medications can only be administrated by intravenously and surgery is done under supervision of medical practioners at these locations.

Geographical Analysis

North America holds the largest market in the global cancer stem cells market due to the high incidence of cancer, according to the International Agency for Research on Cancer (IARC), which claims 13 million new cancer cases worldwide. The World Cancer Report provides that the incidence rate of new cancer cases is increased by 50% to 15 million in 2020. The existence of a highly developed healthcare system, the high degree of acceptance by medical practitioners of novel chemotherapy and radiation therapy methods, the total availability of advanced technological tools, FDA approval of new drugs and also the presence of a vast number of organizations engaged in R&D activities related to cancer vaccines.

The Asia Pacific is expected to be the fastest-growing market over the forecast period owing to increasing prevalence rate, increasing focus on preventive care, and government initiatives promoting technological innovations. For instance, in 2018, Novartis AG Company entered into a license and collaboration agreement with Cellular Biomedicine Group, a clinical stage biopharmaceutical company which improves therapies for cancer and degenerative diseases in China.

Competitive Landscape

The Global Gestational Trophoblastic Disease Market is quite competitive with some key competitors like Bristol-Myers Squibb Company, Antares Pharma, Novartis AG, Teva Pharmaceutical Industries Ltd, BP Pharmaceuticals Laboratories Company, Accord Healthcare, Inc, Eli Lilly and Company, Sanofi, Bayer AG, Amgen Inc, Merck Healthcare KGaA. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, contributing to the market's growth globally. For instance, Eli Lilly and Company - A Phase II Trial of Pemetrexed (Alimta) in the Treatment of Recurrent or Persistent Low Risk Gestational Trophoblastic Tumor.

Merck Healthcare KGaA

Company Overview: Merck KGaA, Germany, a leading science and technology company, operates across healthcare, life science and performance materials. They are headquartered in Darmstadt, with about 58,000 employees and present in 141 countries. The group includes around 250 companies; the leading company is Merck KGaA in Germany. They drive innovation and back entrepreneurs through equity investments and hands-on support in fields that could impact our current and future business. Between our Amsterdam headquarters and American and Israeli offices, our M Ventures team has €300 million under management across four fields: Healthcare, Life Science, Electronics and New Businesses.

Product Portfolio: The Company's portfolio comprised of include Endocrinology, Neurodegenerative diseases, Oncology, Fertility, General medicine and others.

Key developments:

TROPHAMET, a Phase I/II Trial of Avelumab and Methotrexate in Low-risk Gestational Trophoblastic Disease as First Line Treatment.

Why Purchase the Report?

  • Visualize the composition of the Gestational Trophoblastic Disease Market segmentation by Type, Treatment type, End-users, and region highlighting the key commercial assets and players.
  • Identify commercial opportunities in Gestational Trophoblastic Disease Market by analyzing trends and co-development deals.
  • Excel data sheet with thousands of data points of Gestational Trophoblastic Disease Market - level 4/5 segmentation.
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Product mapping in excel for the key product of all major market players

The global Gestational Trophoblastic Disease Market report would provide an access to an approx. 61 market data table, 58 figures and 240 pages.

Target Audience

  • Service Providers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers

Table of Contents

1. Global Gestational Trophoblastic Disease Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Global Gestational Trophoblastic Disease Market - Market Definition and Overview

3. Global Gestational Trophoblastic Disease Market- Executive Summary

  • 3.1. Market Snippet by Type
  • 3.2. Market snippet by Treatment Type
  • 3.3. Market Snippet by End-users
  • 3.4. Market Snippet by Region

4. Global Gestational Trophoblastic Disease Market - Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Uprising in risk factors affecting this spectrum of disease
    • 4.1.2. Restraints:
      • 4.1.2.1. High treatment costs
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Global Gestational Trophoblastic Disease Market - Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Reimbursement Analysis
  • 5.6. Unmet Needs

6. Global Gestational Trophoblastic Disease Market - COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. Global Gestational Trophoblastic Disease Market - By Type

  • 7.1. Introduction
  • 7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type Segment
  • 7.3. Market Attractiveness Index, By Cancer type Segment
      • 7.3.1.1. Hydatidiform mole*
      • 7.3.1.2. Introduction
      • 7.3.1.3. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 7.3.2. Choriocarcinoma
    • 7.3.3. Placental-site trophoblastic tumor
    • 7.3.4. Epithelioid trophoblastic tumor
    • 7.3.5. Others

8. Global Gestational Trophoblastic Disease Market - By Treatment type

  • 8.1. Introduction
  • 8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment type
  • 8.3. Market Attractiveness Index, By Treatment type
    • 8.3.1. Chemotherapy*
      • 8.3.1.1. Introduction
      • 8.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 8.3.2. Surgery
    • 8.3.3. Radiation therapy
    • 8.3.4. Others

9. Global Gestational Trophoblastic Disease Market - By End-users

  • 9.1. Introduction
  • 9.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-users segment
  • 9.3. Market Attractiveness Index, By End-users Segment
    • 9.3.1. Hospitals*
      • 9.3.1.1. Introduction
      • 9.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 9.3.2. Clinics
    • 9.3.3. Cancer research institutes
    • 9.3.4. Others

10. Global Gestational Trophoblastic Disease Market - By Region

  • 10.1. Introduction
  • 10.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
  • 10.3. Market Attractiveness Index, By Region
  • 10.4. North America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End -users
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. U.S.
      • 10.4.6.2. Canada
      • 10.4.6.3. Mexico
  • 10.5. Europe
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End -users
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. Germany
      • 10.5.6.2. U.K.
      • 10.5.6.3. France
      • 10.5.6.4. Italy
      • 10.5.6.5. Spain
      • 10.5.6.6. Rest of Europe
  • 10.6. South America
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End -users
    • 10.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.6.6.1. Brazil
      • 10.6.6.2. Argentina
      • 10.6.6.3. Rest of South America
  • 10.7. Asia Pacific
    • 10.7.1. Introduction
    • 10.7.2. Key Region-Specific Dynamics
    • 10.7.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.7.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.7.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-Users
    • 10.7.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.7.6.1. China
      • 10.7.6.2. India
      • 10.7.6.3. Japan
      • 10.7.6.4. Australia
      • 10.7.6.5. Rest of Asia Pacific
  • 10.8. Middle East and Africa
    • 10.8.1. Introduction
    • 10.8.2. Key Region-Specific Dynamics
    • 10.8.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.8.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.8.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-Users

11. Global Gestational Trophoblastic Disease Market - Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Global Gestational Trophoblastic Disease Market - Company Profiles

  • 12.1. Merck Healthcare KGaA*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Bristol-Myers Squibb Company,
  • 12.3. Antares Pharma,
  • 12.4. Novartis AG,
  • 12.5. Teva Pharmaceutical Industries Ltd,
  • 12.6. BP Pharmaceuticals Laboratories Company,
  • 12.7. Accord Healthcare, Inc,
  • 12.8. Eli Lilly and Company,
  • 12.9. Sanofi,
  • 12.10. Amgen Inc

LIST NOT EXHAUSTIVE

13. Global Gestational Trophoblastic Disease Market - Premium Insights

14. Global Gestational Trophoblastic Disease Market - DataM

  • 14.1. Appendix
  • 14.2. About Us and Services
  • 14.3. Contact Us